Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21021808 | 0.97 | ACACB (0.46) | ACACBPRMT5WDR77KMT2AMEN1 | |
| SCHEMBL21021406 | 0.90 | HDAC1 (0.44) | ACACBPRMT5WDR77 | |
| SCHEMBL21020176 | 0.87 | HDAC1 (0.46) | ACACBPRMT5WDR77 | |
| SCHEMBL21020174 | 0.84 | MAPT (0.38) | PRMT5WDR77KMT2AMEN1L3MBTL1 | |
| SCHEMBL21020840 | 0.82 | MEN1 (0.37) | ACACBPRMT5WDR77KMT2AMEN1 | |
| SCHEMBL21020889 | 0.82 | MEN1 (0.39) | PRMT5WDR77KMT2AMEN1L3MBTL1 | |
| SCHEMBL21020899 | 0.82 | PSMB5 (0.40) | PRMT5WDR77KMT2AMEN1ATM | |
| SCHEMBL21020216 | 0.81 | DRD2 (0.39) | PRMT5KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL21020223 | 0.81 | ACACB (0.37) | ACACBPRMT5KMT2AMEN1L3MBTL1 | |
| SCHEMBL21020893 | 0.80 | CARM1 (0.34) | PRMT5WDR77KMT2AMEN1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | U.S. DEPARTMENT OF ENERGY | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152920-A1 | COMPOUNDS FOR CENTRAL REACTIVATION OF ORGANOPHOSPHORUS- BASED COMPOUND-INHIBITED ACETYLCHOLINESTERASE AND/OR INACTIVATION OF ORGANOPHOSPHORUS-BASED ACETYLCHOLINESTERASE INHIBITORS AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR MAKING AND USING THEM | ACHE, BCHE, CHAT | ACACB 178/4885PRMT5 407/4885WDR77 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.